Superior Quality LGD3303 Powder For Bodybuilding CAS:1196133-39-7

    What Exactly Is LGD3303?

    LGD3303 (chemical designation: 9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one) belongs to a class of compounds called selective androgen receptor modulators-SARMs for short. Originally synthesized at Ligand Pharmaceuticals, this research chemical was never pushed through to FDA approval for human therapeutic use, unlike some better-known SARMs that at least saw phase trials before being shelved.

    Where LGD4033 (better known as Ligandrol) became the darling of underground bodybuilding circles due to its long half-life and user-friendly dosing schedule, LGD3303 occupies a different niche entirely. It's shorter-acting, considerably more potent milligram-for-milligram in certain anabolic endpoints, and produces what experienced users consistently describe as "drier" gains-noticeably less water retention compared to its more popular cousin.

    Understanding LGD3303 requires grasping its fundamental difference from both traditional anabolic steroids and other SARMs. Steroids act like a master key binding indiscriminately to androgen receptors across virtually every tissue type. LGD3303 is smarter: it exhibits what researchers call "functional selectivity," activating androgen receptors fully in some tissues while only partially engaging them in others.

    The raw numbers tell an impressive story about selectivity. LGD3303 binds the human androgen receptor with a Ki value of 0.9 nanomolar, which is extraordinarily tight binding. To put this in perspective, compare its affinities for other nuclear receptors: the mineralocorticoid receptor gets Ki=1261 nM, the glucocorticoid receptor binds at Ki=581 nM, and the progesterone receptor sits at Ki=136 nM. This selectivity profile means LGD3303 is roughly 1,400 times more selective for the androgen receptor than for the mineralocorticoid receptor-a differential that explains much of its tissue-specific behavior.

    In functional assays measuring transcriptional activation, LGD3303 achieves an EC50 of 3.6 nM and demonstrates 134 percent efficacy relative to dihydrotestosterone (DHT), the body's most potent natural androgen. That's not a typo: in certain endpoints, this SARM actually outperforms the reference androgen.

    But here's where the nuance enters. In castrated rat models-males surgically deprived of endogenous androgens-LGD3303 produced dramatically different effects across tissue types. On the levator ani muscle (a proxy for anabolic effect on skeletal muscle), LGD3303 acted as a potent full agonist. At 1 mg per kilogram of body weight daily, it completely prevented muscle loss. At higher doses, it pushed muscle weight above normal intact levels. Contrast this with what happened in the ventral prostate: even at the highest tested doses, prostate weight never exceeded eugonadal (normal) levels, hitting a clear plateau despite escalating compound exposure.

    The 2009 pharmacokinetic-pharmacodynamic study published in the Journal of Pharmacology and Experimental Therapeutics revealed something even more surprising. When researchers measured actual tissue concentrations, they found higher LGD3303 levels in the prostate than in the levator ani muscle-yet the anabolic effect in muscle was stronger, and the androgenic effect in prostate was weaker. This dissociation suggests the mechanism of tissue selectivity operates at the molecular level of the androgen receptor itself, not merely through differential tissue distribution.

    The term "partial agonist" gets thrown around loosely in bodybuilding forums, but its precise meaning matters for understanding LGD3303. A partial agonist binds the same receptor as a full agonist but produces a submaximal response even when all receptors are occupied. On the preputial gland and ventral prostate, LGD3303 behaves exactly this way-a partial agonist. On skeletal muscle, it functions effectively as a full agonist.

    Why does this matter? Because it explains how a compound can be simultaneously extremely anabolic while remaining relatively mild on androgenic target tissues. This is the elusive "anabolic-androgenic dissociation" that researchers have chased for decades.

    Preclinical work has demonstrated additional unique properties. LGD3303 is non-aromatizable, meaning it cannot convert to estrogenic compounds. It effectively crosses the blood-brain barrier, which opens possibilities for central nervous system effects that traditional SARMs may not produce. In rodent studies, LGD3303 enhanced male-directed sexual preference and increased lordosis and proceptivity behaviors-but only in females with prior sexual experience, a fascinating example of experience-dependent modulation.

    The therapeutic rationale that drove LGD3303's original development deserves mention because it explains the compound's unique characteristics. Ligand Pharmaceuticals was exploring treatments for muscle wasting disorders (cachexia, sarcopenia) and osteoporosis. The bone data in particular stands out: LGD3303 activates androgen receptors on osteoblasts, the cells responsible for bone formation, leading to increased bone mineral density and cortical thickness via periosteal apposition-essentially laying down new bone on the outer surface of existing bones. When combined with bisphosphonates, additive effects on bone parameters were observed, suggesting potential synergy for osteoporosis research.

    From a bodybuilding perspective, however, users gravitate toward LGD3303 for distinctly different reasons: rapid strength increases, what some describe as "aggressive" training intensity, acute pumps that appear within hours of dosing, and lean tissue accrual without the watery look associated with compounds like Dianabol or even LGD4033.

    Let's be direct about the evidence base. No published human clinical trials exist for LGD3303. Everything discussed regarding human dosing comes from extrapolation of rodent studies and anecdotal user reports-a significant limitation that any responsible discussion must acknowledge.

    In castrated rats, 1 mg/kg daily completely prevented muscle loss, representing the minimum effective anabolic dose for tissue preservation. Higher doses increased levator ani muscle weight above eugonadal (normal intact) levels. Using standard allometric scaling to convert rat doses to estimated human equivalents (divide by approximately 6.2 for body surface area), the 1 mg/kg rat dose equates to roughly 0.16 mg/kg in humans, or about 11-13 mg for a 75-80 kg individual.

    User-reported dosing patterns generally fall into a range of 10-20 mg daily, divided across two or three administrations due to the compound's short half-life. Some experienced users push toward 30 mg daily, though this substantially increases suppression risk and potential side effects.

    The plasma half-life of LGD3303 appears to be approximately 5 to 6 hours before levels drop off significantly. This is dramatically shorter than LGD4033, which has a half-life around 24-36 hours. The practical implication is clear: achieving stable blood levels requires splitting the daily total into multiple administrations.

    Typical protocols involve taking the compound every 8 to 9 hours-for instance, morning, mid-afternoon, and before bed-or at minimum splitting into two roughly equal doses about 10-12 hours apart. Some users report using a higher dose pre-workout to capitalize on acute effects, with smaller doses at other times to maintain baseline levels.

    This short half-life has both advantages and drawbacks. The upside: if adverse effects emerge, clearance from the system happens relatively quickly. The downside: maintaining consistent anabolic signaling requires discipline with dosing schedules that many users find inconvenient.

    Conventional practice among experienced users suggests cycle lengths of 8 to 12 weeks for LGD3303. For a first-time user unfamiliar with how their body responds to this specific SARM, a shorter initial cycle of 6 weeks allows assessment of tolerance and side effect profile before committing to longer duration.

    A typical first cycle might look like this:

    Weeks 1-6: LGD3303 at 5-10 mg daily, split across two doses. Starting at the lower end (5 mg) for the first 7-10 days allows observation of initial response before potentially titrating upward.

    Weeks 7-8 (for extended cycles): If well tolerated, dosage might increase to 10-15 mg daily, though diminishing returns and amplified suppression must be weighed against incremental gains.

    More advanced users with prior SARM experience sometimes run protocols at 15-20 mg daily for full 10-12 week cycles, but this carries considerably higher risk of significant testosterone suppression.

    Stacking is another variable. Some users combine LGD3303 with non-suppressive compounds like MK-677 (ibutamoren), a ghrelin receptor agonist that increases growth hormone secretion without affecting the HPT axis. Others stack with RAD140 (Testolone) or even other SARMs, though stacking multiple suppressive compounds amplifies the complexity of post-cycle recovery.

    LGD3303 suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in a dose-dependent manner. In rat models, doses above 1 mg/kg produced notable LH suppression, and any dose at or above 10 mg/kg failed to maintain eugonadal LH levels. The practical human translation: even moderate dosing of LGD3303 will suppress natural testosterone production significantly. Some sources estimate SARM-induced LH/FSH suppression in the range of 20 to 40 percent reduction from baseline, with more suppressive compounds like LGD3303 likely falling on the higher end of that spectrum.

    Post-cycle therapy serves to restore the hypothalamic-pituitary-testicular axis (HPTA) to normal function. Without proper PCT, users risk losing a substantial portion of gains, experiencing prolonged low libido, fatigue, mood disturbances, and difficulty maintaining muscle mass.

    A standard PCT protocol following an LGD3303 cycle might include:

    Weeks 1-4 after cycle completion: A SERM (selective estrogen receptor modulator) such as tamoxifen (Nolvadex) at 20 mg daily, or enclomiphene at 12.5-25 mg daily. SERMs block estrogen negative feedback at the pituitary, allowing LH and FSH secretion to resume.

    Supporting supplements: Many users add natural testosterone supports containing ingredients like D-aspartic acid, ashwagandha, and fenugreek to aid the recovery process.

    The critical principle: PCT begins only after the compound has cleared from the system. Given LGD3303's 5-6 hour half-life, 5-6 half-lives (roughly 2-3 days) are sufficient for near-complete clearance before initiating SERM therapy.

    Experienced users describe LGD3303 as producing "dry" muscle gains-meaning the tissue added contains minimal water retention, resulting in a harder, more defined appearance compared to wetter compounds like LGD4033 or traditional steroids. The acute effects are notable even within the first week for some users: increased aggression during training, pronounced muscle pumps, and rapid strength increases. At higher doses, some users report significant size accretion comparable to moderate-dose testosterone cycles.

    The bone density benefits, while less visible and tangible in the short term, represent a genuine point of distinction for LGD3303. Most SARMs have some bone activity, but the periosteal apposition effect-laying down new bone on the outer surface of existing bones-is particularly pronounced with this compound.

    No discussion of LGD3303 is complete without addressing its risks. Testosterone suppression is dose-dependent and significant, with higher doses producing considerable reductions in endogenous androgen production. This is not a "mild" or "bridge-friendly" compound; it's a serious research chemical that requires appropriate respect.

    Lipid profiles can be affected: reductions in HDL (good cholesterol) and increases in LDL (bad cholesterol) have been observed in animal models. The degree of dyslipidemia appears less severe than with oral steroids, but it's not negligible.

    Users who have tried both compounds consistently frame the comparison in a few key dimensions. LGD4033 has a longer half-life, making once-daily dosing sufficient, and produces more pronounced water retention. LGD3303 requires more frequent dosing, yields drier gains, and is described by many as "overall stronger" milligram-for-milligram. The shorter half-life may also mean faster clearance and thus theoretically shorter suppression duration post-cycle, though empirical data on this point remains anecdotal.

Trade names	LGD3303
CAS	1196133-39-7
Molar mass	342.75
MF	C16H14ClF3N2O
Purity	Above 98%
Apprarance	White Cyrstalline Powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    Blood work before, during, and after any cycle is non-negotiable for those who choose to experiment. Liver enzymes, lipid panel, total and free testosterone, LH, FSH, and estradiol provide essential data that guide dosing and PCT decisions.

    LGD3303 represents one of the more potent selective androgen receptor modulators developed to date-but potency cuts both ways. The same molecular features that produce its impressive anabolic effects also demand careful management of dosing, cycle length, and post-cycle recovery. This is not a compound for casual experimenters or those unwilling to commit to proper monitoring. For those who understand the trade-offs and proceed with appropriate precautions, LGD3303 offers a distinct profile among SARM options-dry, strong, and short-acting in a field dominated by longer-duration alternatives.

Hot Tags: superior quality lgd3303 powder for bodybuilding cas:1196133-39-7, China superior quality lgd3303 powder for bodybuilding cas:1196133-39-7 manufacturers, suppliers, factory, LGD3303, MK2866, MK677, OTR-AC, Sarm Powders, SR9011 strengthening the immune system